Skip to main content

Table 7 Univariate analysis of local recurrence in patients treated with perioperative denosumab and curettage for GCTBa (n = 40)

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Comparison of factors No. of local recurrence (%) Univariate analysis
p valueb
All patients (n = 40)
Timing of denosumab
 Preoperative only 6/21 (28.6%) p = 0.719
 Postoperative only 2/9 (22.2%)
Timing of denosumab
 Both pre- and postoperative 0/10 (0.0%) p = 0.068
 Pre- or postoperative only 8/30 (26.7%)
Preoperative (n = 31)
Times of denosumab administration
 5> 5/7 (71.4%) p < 0.001
 5 1/24 (4.2%)
 Timing of denosumab
 Preoperative only 6/21 (28.6%) p = 0.060
 Both pre- and postoperative 0/10 (18.9%)
Postoperative (n = 19)
 Times of denosumab administration
 5> 0/7 (0.0%) p = 0.253
 5 2/12 (16.7%)
Embolization before surgery
 Postoperative only 2/9 (22.2%) p = 0.115
 Both pre- and postoperative 0/10 (0.0%)
  1. aGCTB, giant cell tumor of bone
  2. bChi-square test